Altimmune, INC Form 4 insider transactions

Altimmune, Inc. Director Jerome Benedict Durso plans to purchase 12,500 shares of common stock on December 22, 2025, at a weighted average price of $4.1255.

Altimmune, Inc. announced the appointment of Jerome Benedict Durso as President and CEO effective January 1, 2026, accompanied by substantial equity awards.

Altimmune's CFO, Gregory L. Weaver, reported the vesting of 18,750 Restricted Stock Units and a subsequent sale of 5,672 shares to cover tax obligations.

Altimmune's Chief Financial Officer, Gregory L. Weaver, was granted 166,800 stock options and 57,900 Restricted Stock Units, vesting over four years.

Altimmune's Chief Medical Officer, Christophe Arbet-Engels, was granted 450,000 stock options and 150,000 Restricted Stock Units.

Altimmune, Inc. Director Catherine A. Sohn was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune, Inc. Director Jerome Benedict Durso was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune, Inc. Director Teri L Lawver was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune Director Diane Jorkasky was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune Director John Gill reported the acquisition of 48,800 stock options and a gift of 2,714 common shares, adjusting his direct common stock ownership to zero.

Altimmune, Inc. director Klaus Schafer was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months starting September 25, 2025.

Altimmune, Inc. Director Mitchel Sayare was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months starting September 25, 2025.

Altimmune, Inc. Director Philip Hodges was granted 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune, Inc. Director Wayne Pisano received a grant of 48,800 stock options with an exercise price of $3.92, vesting over 12 months.

Altimmune's Chief Commercial Officer, Linda M Richardson, was granted 278,000 stock options and 96,000 Restricted Stock Units.

Altimmune's Chief Business Officer, Raymond M. Jordt, acquired 1,368 shares of common stock through the company's Employee Stock Purchase Plan.

Altimmune's Chief Medical Officer, Matthew Scott Harris, acquired 2,018 shares of common stock through the company's Employee Stock Purchase Plan at a discounted price of $3.14 per share.

Altimmune's Chief Scientific Officer, M. Scot Roberts, acquired 846 shares of common stock through the company's Employee Stock Purchase Plan at $3.14 per share.

Director Catherine A. Sohn of Altimmune, Inc. purchased 1,000 shares of common stock at a price of $5.7845 on March 17, 2025.

Altimmune's Chief Financial Officer, Gregory L. Weaver, recently purchased 10,000 shares of the company's common stock at an average price of $5.1996 per share.

Altimmune's Chief Medical Officer, Matthew Scott Harris, transferred 67,787 shares of common stock to the Matthew Scott Harris Trust on March 7, 2025.

Director Teri L. Lawver acquired 69,800 stock options in Altimmune, Inc. on February 24, 2025, according to a Form 4 filing with the SEC.

Altimmune director Jerome Benedict Durso acquired 69,800 stock options on February 24, 2025, exercisable over the next ten years.

Catherine A. Sohn, a director of Altimmune, Inc., reported the acquisition of stock options to purchase 18,600 shares of common stock.

Altimmune's CEO, Vipin K. Garg, reported multiple transactions involving the company's stock, including the vesting of restricted stock units and purchases through the employee stock purchase plan.

Altimmune's Chief Medical Officer, Matthew Scott Harris, reported multiple transactions involving the company's stock, including the vesting of restricted stock units and purchases through the employee stock purchase plan.

Altimmune's Chief Business Officer, Raymond M Jordt, acquired 2,614 shares of common stock through the company's Employee Stock Purchase Plan (ESPP) at a price of $5.18 per share.

Altimmune's Chief Scientific Officer, M. Scot Roberts, reported multiple transactions involving the company's common stock and restricted stock units.

M. Scot Roberts, Chief Scientific Officer of Altimmune, Inc., reported the acquisition of restricted stock units and stock options, as well as the disposition of shares to cover taxes.

Altimmune's Chief Business Officer, Raymond Jordt, reports the acquisition and disposal of company stock and stock options.